Latest News
Search News :

Production of two new blood pressure medicines in the country

1-min
January 23, 2024

Author:

Acteropharma
Specialists at a pharmaceutical company have developed two new drugs to treat high blood pressure, a condition that affects approximately 32 million Iranians to varying degrees. The CEO of Actoverco pharmaceutical group, Reza Karimi Mostofi, reported that the specialists of his group have successfully provided the blood pressure medication Telmic-H to patients in Iran. Telmic-H is the first medication of its kind in Iran, containing telmisartan/hydrochlorothiazide. This medication comes in the form of coated tablets in two strengths: 80/12.5 and 80/25 mg. It is commonly used to treat high blood pressure. He stated that approximately 32 million people in Iran suffer from high blood pressure, which is one of the leading causes of cardiovascular diseases, including heart attacks, strokes, and fatalities resulting from these conditions.Cardiovascular accidents tend to occur more frequently in the early morning hours when the balance of certain hormones in the body is disrupted. Telmisartan/hydrochlorothiazide Actoverco medicine has several benefits, including constant monitoring of blood pressure, especially during sleep at night and in the early morning, which helps in maintaining a healthy blood pressure level. Mostofi stated that taking this medication can regulate blood pressure for 24 hours and minimize side effects. He mentioned that the company has introduced another new medicine named Irbesal (Irbesartan) at the Salamat Bonyan exhibition of science-based products in the field of food, medicine, and medical equipment. Irbesal is available in the form of coated and lined tablets of 300mg. Actoverco’s CEO stated that this drug is used to treat high blood pressure and diabetic nephropathy. He pointed out that high blood pressure, which unfortunately is quite prevalent in the country, is one of the leading causes of cardiovascular and kidney diseases. He affirmed that high blood pressure complications in diabetic patients, with uncontrolled high blood sugar, can cause damage to the kidney vessels and cells. This damage to cells will eventually lead to kidney failure.In addition to controlling blood pressure, Irbesartan can be effective in preventing diabetic nephropathy, which is the excretion of protein from the kidneys. The CEO of Actoverco Pharmaceuticals has stated that their company produces almost 400 different pharmaceutical products across 15 therapeutic areas. These products range from general disease treatments to high-risk oncology, hormonal, and biological drugs. The pharmaceutical complex is also involved in producing raw materials and supplements. To support the development of knowledge-based activities in the healthcare field, the Actotech accelerator has been launched. Mostofi stated that the knowledge-based complex became operational in 2020. The complex was inaugurated by the president’s scientific and technological deputy and the secretary of the biotechnology development staff. Currently, it is an advanced research and development complex that fulfills the requirements of a science and technology park. It supports the commercialization of innovative ideas across various fields, such as biotechnology drugs, vaccines, new drug formulations, personalized medicine, smart health, diagnostic kits, food quality control, as well as the field of raw materials, and factory production line equipment.

Merck, Actover’s reliable partner in the transfer of the most advanced pharmaceutical technologies to Iran

همکاری اکتوور با مرک
January 23, 2024

Author:

Acteropharma
Merck, a German company, is one of the oldest manufacturers of drugs, chemicals, and health materials globally, and it is a leading name in the research and development (R&D) field in these sectors. The company exports its products to over 60 countries worldwide and is renowned for its innovative technology in the pharmaceutical industry. Merck’s production groups manufacture over 20,000 specialized pharmaceuticals, laboratory products, and special chemicals across various sectors. This company has started its activity in the field of trading and selling drugs in Iran since 1968. Actover Pharmaceutical Company has been successfully present in the Iranian pharmaceutical market for over half a century. They have achieved this with the help of the highest standards and the most advanced technologies and equipment in the world. As a result, they have gained the attention of major foreign companies, including Merck. Actovar is a company committed to producing high-quality pharmaceutical products using the latest technology, expert personnel, and smart selection of new products. It is proud to have obtained the highest quality standards and approvals, making it a capable partner of Merck in Iran and the surrounding region. It’s partnership allows it to produce drugs for this large German company and provide easy and affordable access to the latest pharmaceutical innovations from Merck

EHA 2023 Actero Sponsorship

EHA 2023
June 26, 2023

Author:

Acteropharma

Actero Support in Congress 1400

Site
July 24, 2022

Author:

Acteropharma
Actero company’s social respomsibility of patient support in Hematology-Oncology Congress and Radiation Therapy Congress

Best of ASCO 2021

Dr-noroozi-event-2048x1367
November 16, 2021

Author:

Acteropharma
The aforesaid seminar has been held for the first time in Iran with the hospitality of Isfahan city, with the cooperation of Radiation-Oncologists from all over of the country and Actero Pharma.

“Uro-Oncology Tumor board: Challenges of Prostate Cancer Treatment” (Semi-Virtual)

Dr-noroozi-event-2048x1367
November 16, 2021

Author:

Acteropharma
Uro-Oncology research Center of Tehran University of Medical science, in cooperation with Actero Pharma has held a semi-virtual tumor board.

Lung Cancer & COVID-19 Webinar.

Webp.net-gifmaker-3
December 20, 2020

Author:

Acteropharma
Regarding the Importance of experience sharing about Lung cancer patients with COVID-19 complications, a multidisciplinary virtual Meeting was held on December 3rd 2020 …

“Updates on Colorectal Cancer” Webinar

Webp.net-gifmaker-2
December 20, 2020

Author:

Acteropharma
“Updates On Colorectal Cancer”, a cooperative event by Iranian Society of Radiation Oncology (ISRO) & Actero

Spending the cost of Bortezomib ACTe launch for the first injection of patients in need.

7
October 20, 2020

Author:

Acteropharma
Considering the current situation in the country and taking into account the needs of patients, Actero Company decided to spend all the costs related to the unveiling of the drug Bortezomib ACTe on the first free injection of patients’ candidates receiving Bortezomib.

Breast Cancer Webinar

6
October 20, 2020

Author:

Acteropharma
Simultaneously with the unveiling of Onkotaxel (Docetaxel of Actero Company), a subspecialized webinar was held on July 23rd with the presence of Dr. Safa Najafi (Medical Oncologist), Dr. Samiei (Radiotherapy Oncologist), Dr. Azimi Nejadan (Surgeon) and Ms. Dr. Ehsani (Pathologist) on August 2.

Production and launch of Favipiravir and Remdesivir in Actover Pharma group

4
October 20, 2020

Author:

Acteropharma
With continuous monitoring of international research and protocols, it was suggested to produce drugs in the treatment of Covid-19 in the Actover group, as a pioneer in the production of drugs needed in Covid 19, the group unveiled two drugs, Remdesivir and Favipiravir.

Injection production line opening

ezgif-4-121aa3c9338f
October 20, 2020

Author:

Acteropharma
After opening and operating the injection drug production line last year and increasing its production capacity in order to expand the product basket portfolio in the New Year, Actero factory, which specializes in the production of cancer drugs, intends to meet the needs of cancer patients in most treatment protocols.